Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Schlehuber, S., & Skerra, A. (2001) Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol. Chem. 382, 1335-1342.
Key Takeaway: The article discusses engineered ligand-binding proteins known as Duocalins, derived from the lipocalin fold. It references a study by Schlehuber and Skerra published in 2001. The content appears to be a placeholder with no specific insights or developments in the biopharma field.
Price reaction · baseline $22.05 (2025-06-20 close) · 23 other PVLA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita